GSK Licenses Ex-China Rights to HUTCHMED’s KRAS-EGFR Conjugate

Companies: HUTCHMED / GSK · Asset: HMPL-A830 (Anti-EGFR + KRAS Inhibitor Conjugate) · Deal Terms: $110M Upfront + up to $1.185B Milestones · Territory: Ex-Greater China · Date: September 3, 2026 Summary HUTCHMED granted a GSK subsidiary exclusive rights outside Greater China to HMPL-A830, a…